Atwood & Palmer’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$44.2M Buy
350,240
+2,801
+0.8% +$369K 2.36% 13
2026
Q1
$48.4M Sell
347,439
-2,396
-0.7% -$336K 2.73% 8
2025
Q4
$42.9M Buy
349,835
+5,685
+2% +$691K 2.44% 11
2025
Q3
$38.2M Buy
344,150
+68
+0% +$7.73K 2.24% 13
2025
Q2
$38.1M Sell
344,082
-985
-0.3% -$105K 2.38% 12
2025
Q1
$38.7M Sell
345,067
-4,189
-1% -$432K 2.68% 6
2024
Q4
$32.3M Buy
349,256
+2,576
+0.7% +$232K 2.21% 15
2024
Q3
$29.1M Buy
346,680
+736
+0.2% +$56.2K 1.98% 19
2024
Q2
$23.7M Sell
345,944
-850
-0.2% -$56.7K 1.8% 24
2024
Q1
$25.4M Buy
346,794
+8,375
+2% +$644K 1.93% 21
2023
Q4
$27.4M Buy
338,419
+475
+0.1% +$37K 2.22% 16
2023
Q3
$25.3M Buy
337,944
+1,195
+0.4% +$91.9K 2.22% 18
2023
Q2
$26M Buy
336,749
+89,479
+36% +$7.14M 2.32% 15
2023
Q1
$20.5M Buy
247,270
+244
+0.1% +$20.2K 1.93% 20
2022
Q4
$21.2M Buy
247,026
+4,390
+2% +$348K 1.92% 17
2022
Q3
$15M Buy
242,636
+5,506
+2% +$347K 1.48% 26
2022
Q2
$14.7M Buy
237,130
+4,387
+2% +$272K 1.43% 30
2022
Q1
$13.8M Buy
232,743
+4,605
+2% +$294K 1.19% 36
2021
Q4
$16.6M Buy
228,138
+10,196
+5% +$702K 1.39% 31
2021
Q3
$15.2M Buy
217,942
+3,300
+2% +$232K 1.36% 32
2021
Q2
$14.8M Buy
214,642
+6,338
+3% +$423K 1.33% 32
2021
Q1
$13.5M Buy
208,304
+1,293
+0.6% +$83.4K 1.3% 32
2020
Q4
$12.1M Buy
207,011
+1,897
+0.9% +$114K 1.29% 31
2020
Q3
$13M Sell
205,114
-422
-0.2% -$29.3K 1.63% 25
2020
Q2
$15.8M Sell
205,536
-3,473
-2% -$266K 2.14% 20
2020
Q1
$15.6M Buy
209,009
+1
+0% +$69 2.45% 14
2019
Q4
$13.6M Sell
209,008
-9,731
-4% -$634K 1.75% 23
2019
Q3
$13.9M Sell
218,739
-2,114
-1% -$138K 1.87% 23
2019
Q2
$14.9M Buy
220,853
+282
+0.1% +$18.6K 2.02% 20
2019
Q1
$14.3M Buy
220,571
+257
+0.1% +$17.1K 2.03% 19
2018
Q4
$13.8M Sell
220,314
-694
-0.3% -$48.5K 2.19% 18
2018
Q3
$17.1M Buy
221,008
+652
+0.3% +$49.2K 2.23% 18
2018
Q2
$15.6M Sell
220,356
-4,032
-2% -$285K 2.14% 16
2018
Q1
$16.9M Sell
224,388
-2,390
-1% -$190K 2.41% 15
2017
Q4
$16.2M Sell
226,778
-490
-0.2% -$37.2K 2.28% 18
2017
Q3
$18.4M Sell
227,268
-2,274
-1% -$174K 2.67% 16
2017
Q2
$16.2M Buy
229,542
+3,442
+2% +$229K 2.55% 19
2017
Q1
$15.4M Sell
226,100
-6,919
-3% -$487K 2.45% 19
2016
Q4
$16.7M Sell
233,019
-2,606
-1% -$194K 3% 12
2016
Q3
$18.6M Sell
235,625
-2,023
-0.9% -$164K 3.39% 7
2016
Q2
$19.8M Buy
237,648
+1,172
+0.5% +$104K 3.58% 6
2016
Q1
$21.7M Buy
236,476
+55,826
+31% +$5.03M 3.86% 3
2015
Q4
$18.3M Buy
180,650
+3,901
+2% +$406K 3.47% 4
2015
Q3
$17.4M Buy
176,749
+11,136
+7% +$1.24M 3.39% 3
2015
Q2
$19.4M Buy
165,613
+226
+0.1% +$24.7K 3.49% 3
2015
Q1
$16.2M Sell
165,387
-320
-0.2% -$32.5K 2.9% 5
2014
Q4
$15.6M Sell
165,707
-6,125
-4% -$633K 2.92% 6
2014
Q3
$18.3M Buy
171,832
+45,944
+36% +$4.5M 3.45% 4
2014
Q2
$10.4M Sell
125,888
-48,539
-28% -$3.78M 2.78% 4
2014
Q1
$12.4M Buy
174,427
+3,643
+2% +$286K 2.89% 9
2013
Q4
$12.8M Buy
170,784
+750
+0.4% +$52.2K 3.16% 10
2013
Q3
$10.7M Buy
170,034
+1,130
+0.7% +$67.5K 2.95% 13
2013
Q2
$8.66M Buy
+168,904
New +$8.8M 2.34% 15

Other funds holding GILD

Atwood & Palmer's GILD Position: Q2 2026 in Review

Atwood & Palmer increased its Gilead Sciences (GILD) stake by 0.81% in Q2 2026, buying an estimated $369K and bringing the position to 350,240 shares worth $44.2M. The position accounts for 2.36% of the portfolio, ranked #13.

Atwood & Palmer first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $48.4M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Atwood & Palmer held 350,240 shares of Gilead Sciences worth $44.2M as of Q2 2026.
  • Atwood & Palmer bought 2,801 Gilead Sciences shares in Q2 2026, an estimated $369K.
  • Gilead Sciences made up 2.36% of Atwood & Palmer's portfolio in Q2 2026, its #13 holding.
  • Atwood & Palmer first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • Atwood & Palmer's Gilead Sciences position peaked at $48.4M in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Atwood & Palmer's 13F filing for Q2 2026, filed 8 Jul 2026.